 |
PDBsum entry 3cen
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
|
|
Title
|
|
Structure-Activity relationships of anthranilamide-Based factor xa inhibitors containing piperidinone and pyridinone p4 moieties.
|
|
|
Authors
|
|
J.R.Corte,
T.Fang,
D.J.Pinto,
W.Han,
Z.Hu,
X.J.Jiang,
Y.L.Li,
J.F.Gauuan,
M.Hadden,
D.Orton,
A.R.Rendina,
J.M.Luettgen,
P.C.Wong,
K.He,
P.E.Morin,
C.H.Chang,
D.L.Cheney,
R.M.Knabb,
R.R.Wexler,
P.Y.Lam.
|
|
|
Ref.
|
|
Bioorg Med Chem Lett, 2008,
18,
2845-2849.
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
Introduction of the phenyl piperidinone and phenyl pyridinone P4 moieties in the
anthranilamide scaffold led to potent, selective, and orally bioavailable
inhibitors of factor Xa. Anthranilamide 28 displayed comparable efficacy to
apixaban in the rabbit arteriovenous-shunt (AV) thrombosis model.
|
|
|
|
|
|
|
